Literature DB >> 19951992

Deficiency of pRb family proteins and p53 in invasive urothelial tumorigenesis.

Feng He1, Lan Mo, Xiao-Yong Zheng, Changkun Hu, Herbert Lepor, Eva Y-H P Lee, Tung-Tien Sun, Xue-Ru Wu.   

Abstract

Defects in pRb tumor suppressor pathway occur in approximately 50% of the deadly muscle-invasive urothelial carcinomas in humans and urothelial carcinoma is the most prevalent epithelial cancer in long-term survivors of hereditary retinoblastomas caused by loss-of-function RB1 mutations. Here, we show that conditional inactivation of both RB1 alleles in mouse urothelium failed to accelerate urothelial proliferation. Instead, it profoundly activated the p53 pathway, leading to extensive apoptosis, and selectively induced pRb family member p107. Thus, pRb loss triggered multiple fail-safe mechanisms whereby urothelial cells evade tumorigenesis. Additional loss of p53 in pRb-deficient urothelial cells removed these p53-dependent tumor barriers, resulting in late-onset hyperplasia, umbrella cell nuclear atypia, and rare-occurring low-grade, superficial papillary bladder tumors, without eliciting invasive carcinomas. Importantly, mice deficient in both pRb and p53, but not those deficient in either protein alone, were highly susceptible to subthreshold carcinogen exposure and developed invasive urothelial carcinomas that strongly resembled the human counterparts. The invasive lesions had a marked reduction of p107 but not p130 of the pRb family. Our data provide compelling evidence, indicating that urothelium, one of the slowest cycling epithelia, is remarkably resistant to transformation by pRb or p53 deficiency; that concurrent loss of these two tumor suppressors is necessary but insufficient to initiate urothelial tumorigenesis along the invasive pathway; that p107 may play a critical role in suppressing invasive urothelial tumor formation; and that replacing/restoring the function of pRb, p107, or p53 could be explored as a potential therapeutic strategy to block urothelial tumor progression.

Entities:  

Mesh:

Substances:

Year:  2009        PMID: 19951992      PMCID: PMC2794922          DOI: 10.1158/0008-5472.CAN-09-2158

Source DB:  PubMed          Journal:  Cancer Res        ISSN: 0008-5472            Impact factor:   12.701


  46 in total

1.  p53 and RB: simple interesting correlates or tumor markers of critical predictive nature?

Authors:  Carlos Cordon-Cardo
Journal:  J Clin Oncol       Date:  2004-02-23       Impact factor: 44.544

2.  Identification of fibroblast growth factor receptor 3 mutations in urine sediment DNA samples complements cytology in bladder tumor detection.

Authors:  Kimberly M Rieger-Christ; Arthur Mourtzinos; Peter J Lee; Ralph M Zagha; Jason Cain; Mark Silverman; John A Libertino; Ian C Summerhayes
Journal:  Cancer       Date:  2003-08-15       Impact factor: 6.860

Review 3.  p53: guardian of the genome and policeman of the oncogenes.

Authors:  Alejo Efeyan; Manuel Serrano
Journal:  Cell Cycle       Date:  2007-05-28       Impact factor: 4.534

4.  p53 deficiency provokes urothelial proliferation and synergizes with activated Ha-ras in promoting urothelial tumorigenesis.

Authors:  Jing Gao; Hong-Ying Huang; Joanne Pak; Jin Cheng; Zhong-Ting Zhang; Ellen Shapiro; Angel Pellicer; Tung-Tien Sun; Xue-Ru Wu
Journal:  Oncogene       Date:  2004-01-22       Impact factor: 9.867

Review 5.  Molecular pathogenesis of bladder cancer.

Authors:  Margaret A Knowles
Journal:  Int J Clin Oncol       Date:  2008-08-15       Impact factor: 3.402

6.  Cell type-specific effects of Rb deletion in the murine retina.

Authors:  David MacPherson; Julien Sage; Teresa Kim; Dennis Ho; Margaret E McLaughlin; Tyler Jacks
Journal:  Genes Dev       Date:  2004-07-01       Impact factor: 11.361

7.  Allelic loss of p53 gene is associated with genesis and maintenance, but not invasion, of mouse carcinoma in situ of the bladder.

Authors:  Jin Cheng; Hongying Huang; Joanne Pak; Ellen Shapiro; Tung-Tien Sun; Carlos Cordon-Cardo; Frederic M Waldman; Xue-Ru Wu
Journal:  Cancer Res       Date:  2003-01-01       Impact factor: 12.701

8.  Lifetime risks of common cancers among retinoblastoma survivors.

Authors:  Olivia Fletcher; Douglas Easton; Kristin Anderson; Clare Gilham; Marcelle Jay; Julian Peto
Journal:  J Natl Cancer Inst       Date:  2004-03-03       Impact factor: 13.506

Review 9.  From G0 to S phase: a view of the roles played by the retinoblastoma (Rb) family members in the Rb-E2F pathway.

Authors:  Ang Sun; Luigi Bagella; Steven Tutton; Gaetano Romano; Antonio Giordano
Journal:  J Cell Biochem       Date:  2007-12-15       Impact factor: 4.429

Review 10.  If cystectomy is insufficient, what is an urologist to do?

Authors:  H Barton Grossman; Colin P N Dinney
Journal:  Urol Oncol       Date:  2003 Nov-Dec       Impact factor: 3.498

View more
  41 in total

1.  The role of WNT signalling in urothelial cell carcinoma.

Authors:  I Ahmad
Journal:  Ann R Coll Surg Engl       Date:  2015-08-14       Impact factor: 1.891

Review 2.  Molecular Characterization of Bladder Cancer.

Authors:  Thenappan Chandrasekar; Annette Erlich; Alexandre R Zlotta
Journal:  Curr Urol Rep       Date:  2018-11-03       Impact factor: 3.092

3.  Stat3 activation in urothelial stem cells leads to direct progression to invasive bladder cancer.

Authors:  Philip Levy Ho; Erica Julianne Lay; Weiguo Jian; Diana Parra; Keith Syson Chan
Journal:  Cancer Res       Date:  2012-04-24       Impact factor: 12.701

4.  In vivo disruption of an Rb-E2F-Ezh2 signaling loop causes bladder cancer.

Authors:  Mirentxu Santos; Mónica Martínez-Fernández; Marta Dueñas; Ramón García-Escudero; Begoña Alfaya; Felipe Villacampa; Cristina Saiz-Ladera; Clotilde Costa; Marta Oteo; José Duarte; Victor Martínez; Mª José Gómez-Rodriguez; Mª Luisa Martín; Manoli Fernández; Patrick Viatour; Miguel A Morcillo; Julien Sage; Daniel Castellano; Jose L Rodriguez-Peralto; Federico de la Rosa; Jesús M Paramio
Journal:  Cancer Res       Date:  2014-09-24       Impact factor: 12.701

5.  ATDC/TRIM29 Drives Invasive Bladder Cancer Formation through miRNA-Mediated and Epigenetic Mechanisms.

Authors:  Phillip L Palmbos; Lidong Wang; Huibin Yang; Yin Wang; Jacob Leflein; McKenzie L Ahmet; John E Wilkinson; Chandan Kumar-Sinha; Gina M Ney; Scott A Tomlins; Stephanie Daignault; Lakshmi P Kunju; Xue-Ru Wu; Yair Lotan; Monica Liebert; Mats E Ljungman; Diane M Simeone
Journal:  Cancer Res       Date:  2015-10-15       Impact factor: 12.701

6.  Clinicopathologic and Genomic Characterization of PD-L1 Positive Urothelial Carcinomas.

Authors:  Richard S P Huang; James Haberberger; Lukas Harries; Eric Severson; Daniel L Duncan; N Lynn Ferguson; Amanda Hemmerich; Claire Edgerly; Karthikeyan Murugesan; Jinpeng Xiao; Deborah McEwan; Oliver Holmes; Matthew Hiemenz; Jeffrey Venstrom; Julia A Elvin; James Creeden; Douglas I Lin; Jeffrey S Ross; Shakti H Ramkissoon
Journal:  Oncologist       Date:  2021-03-25

Review 7.  Modelling bladder cancer in mice: opportunities and challenges.

Authors:  Takashi Kobayashi; Tomasz B Owczarek; James M McKiernan; Cory Abate-Shen
Journal:  Nat Rev Cancer       Date:  2015-01       Impact factor: 60.716

8.  Methods to assess anticancer immune responses in orthotopic bladder carcinomas.

Authors:  Randy F Sweis
Journal:  Methods Enzymol       Date:  2019-10-24       Impact factor: 1.600

9.  Oncogenic HRAS Activates Epithelial-to-Mesenchymal Transition and Confers Stemness to p53-Deficient Urothelial Cells to Drive Muscle Invasion of Basal Subtype Carcinomas.

Authors:  Feng He; Jonathan Melamed; Moon-Shong Tang; Chuanshu Huang; Xue-Ru Wu
Journal:  Cancer Res       Date:  2015-03-20       Impact factor: 12.701

Review 10.  Interstitial calcinosis in renal papillae of genetically engineered mouse models: relation to Randall's plaques.

Authors:  Xue-Ru Wu
Journal:  Urolithiasis       Date:  2014-08-06       Impact factor: 3.436

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.